LM_ID
|
Common Name
|
Systematic Name
|
Main class
|
Sub class
|
Mass
|
Formula
|
LMFA04010134
|
20-epi-20-F4t-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010065
|
4,11-diepi-11-F4c-NeuroP
|
3-((1S,2S,3S,5R)-3,5-dihydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010064
|
4,11-diepi-11-F4t-NeuroP
|
3-((1R,2R,3S,5R)-3,5-dihydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010017
|
4,7-diepi-4-F4c-NeuroP
|
(R,E)-6-((1S,2S,3R,5S)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010016
|
4,7-diepi-4-F4t-NeuroP
|
(R,E)-6-((1R,2R,3R,5S)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010008
|
4-F4-NeuroP
|
(E)-6-(3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010023
|
4-F4c-NeuroP
|
(S,E)-6-((1R,2S,3R,5S)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010026
|
4-F4t-NeuroP
|
(S,E)-6-((1S,2R,3R,5S)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010073
|
4-epi-11-F4c-NeuroP
|
3-((1S,2S,3R,5S)-3,5-dihydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010072
|
4-epi-11-F4t-NeuroP
|
3-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010015
|
4-epi-4-F4c-NeuroP
|
(R,E)-6-((1R,2S,3R,5S)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010018
|
4-epi-4-F4t-NeuroP
|
(R,E)-6-((1S,2R,3R,5S)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010033
|
7,10-diepi-7-F4c-NeuroP
|
(R,4Z,8E)-9-((1S,2S,3R,5S)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010032
|
7,10-diepi-7-F4t-NeuroP
|
(R,4Z,8E)-9-((1R,2R,3R,5S)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010101
|
7,14-diepi-14-F4c-NeuroP
|
(Z)-6-((1S,2S,3R,5S)-3,5-dihydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010100
|
7,14-diepi-14-F4t-NeuroP
|
(Z)-6-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010007
|
7-F4-NeuroP
|
(4Z,8E)-9-(3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010039
|
7-F4c-NeuroP
|
(S,4Z,8E)-9-((1R,2S,3R,5S)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010042
|
7-F4t-NeuroP
|
(S,4Z,8E)-9-((1S,2R,3R,5S)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010105
|
7-epi-14-F4c-NeuroP
|
(Z)-6-((1S,2S,3R,5S)-3,5-dihydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010010
|
7-epi-14-F4t-NeuroP
|
8S,10R,14S-trihydroxy-4Z,12E,16Z,19Z-neuroprostatetraenoic acid-cyclo[7R,11R]
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010025
|
7-epi-4-F4c-NeuroP
|
(S,E)-6-((1S,2S,3R,5S)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010024
|
7-epi-4-F4t-NeuroP
|
(S,E)-6-((1R,2R,3R,5S)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010031
|
7-epi-7-F4c-NeuroP
|
(R,4Z,8E)-9-((1R,2S,3R,5S)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010034
|
7-epi-7-F4t-NeuroP
|
(R,4Z,8E)-9-((1S,2R,3R,5S)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010052
|
ent-10,13-diepi-4-Fc-NeuroP
|
(S,4Z,7Z,11E)-12-((1R,2R,3S,5R)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010053
|
ent-10,13-diepi-4-Ft-NeuroP
|
(S,4Z,7Z,11E)-12-((1S,2S,3S,5R)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010112
|
ent-10,17-diepi-17-F4c-NeuroP
|
(4Z,7Z)-9-((1R,2R,3S,5R)-3,5-dihydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010113
|
ent-10,17-diepi-17-F4t-NeuroP
|
(4Z,7Z)-9-((1S,2S,3S,5R)-3,5-dihydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010046
|
ent-10-F4c-NeuroP
|
(R,4Z,7Z,11E)-12-((1S,2R,3S,5R)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010043
|
ent-10-F4t-NeuroP
|
(R,4Z,7Z,11E)-12-((1R,2S,3S,5R)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010108
|
ent-10-epi-17-F4c-NeuroP
|
(4Z,7Z)-9-((1R,2R,3S,5R)-3,5-dihydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010109
|
ent-10-epi-17-F4t-NeuroP
|
(4Z,7Z)-9-((1S,2S,3S,5R)-3,5-dihydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010054
|
ent-10-epi-4-Fc-NeuroP
|
(S,4Z,7Z,11E)-12-((1S,2R,3S,5R)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010051
|
ent-10-epi-4-Ft-NeuroP
|
(S,4Z,7Z,11E)-12-((1R,2S,3S,5R)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010028
|
ent-10-epi-7-F4c-NeuroP
|
(R,4Z,8E)-9-((1R,2R,3S,5R)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010029
|
ent-10-epi-7-F4t-NeuroP
|
(R,4Z,8E)-9-((1S,2S,3S,5R)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010062
|
ent-11-F4c-NeuroP
|
3-((1S,2R,3S,5R)-3,5-dihydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010059
|
ent-11-F4t-NeuroP
|
3-((1R,2S,3S,5R)-3,5-dihydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010070
|
ent-11-epi-4-Fc-NeuroP
|
3-((1S,2R,3R,5S)-3,5-dihydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010067
|
ent-11-epi-4-Ft-NeuroP
|
3-((1R,2S,3R,5S)-3,5-dihydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010084
|
ent-13,16-diepi-13-F4c-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1R,2R,3S,5R)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010085
|
ent-13,16-diepi-13-F4t-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1S,2S,3S,5R)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010128
|
ent-13,20-diepi-20-F4c-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2R,3S,5R)-3,5-dihydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010129
|
ent-13,20-diepi-20-F4t-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2S,3S,5R)-3,5-dihydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010078
|
ent-13-F4c-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1S,2R,3S,5R)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010075
|
ent-13-F4t-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1R,2S,3S,5R)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010044
|
ent-13-epi-10-F4c-NeuroP
|
(R,4Z,7Z,11E)-12-((1R,2R,3S,5R)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010045
|
ent-13-epi-10-F4t-NeuroP
|
(R,4Z,7Z,11E)-12-((1S,2S,3S,5R)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
LMFA04010086
|
ent-13-epi-13-F4t-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1S,2R,3S,5R)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|